Lastly, we note that our study has a much larger percentage of BRAFV600E/V600E melanomas compared to other studies, which could explain why BRAF zygosity had a stronger association with sensitivity to PLX4720 treatment in our study compared to others. This evidence concerns the gene BRAF and melanoma.